Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Dr Karen Venter
Dr Venter received her PhD at the December graduation ceremonies. She focused on addressing societal challenges through the practice of engaged scholarship in community-university research partnerships for the common good.

When asked what inspired her to pursue a PhD, Dr Karen Venter, Head of the Division of Service Learning in the Directorate Community Engagement at the University of the Free State (UFS), said she wanted to make a difference in addressing societal challenges through the practice of engaged scholarship in community-university research partnerships for the common good. 

“Also, I love to learn and share knowledge – and that is exactly what I did in this PhD, titled: An integrated service-learning praxis approach for flourishment of professional development in community-higher education partnerships.” 

She explains, “My five-articles-style thesis explored the contribution of an integrated service-learning praxis approach towards the flourishment of engaged scholarship in community-higher education partnerships. The approach combined community engaged service-learning (CESL), appreciative inquiry and appreciative leadership, to advance the praxis of engaged scholarship. The study was demarcated in the field of higher education, applied in the discipline of nursing education, and contextually bound to three interrelated action research cycles and settings – for international, national, and local level engagement.”

Community members participate in the research journey

“The intent of the study was to recognise the community-led action learning of community member participants at the core action learning set,” says Dr Venter. 

The study followed a participatory action learning and action research methodology. During her research journey, she was joined by members of the community, specifically from Bloemshelter – a shelter for the homeless. “They co-constructed and completed a four-year community-led action learning pathway to holistic development (spiritual, personal, professional), which brought about holistic social change and well-being in their livelihood, moving from dependence on others to establishing viable multiple micro-enterprises,” she says.

The UFS affiliated with GULL to reward the community member participants’ action learning. “Already in 2019, GULL certified their action learning with a Professional Bachelor’s degree, while I still had to document the action research, and only now received the PhD,” says Dr Venter. 

“I am grateful to all the participants who co-created action-oriented knowledge with me in the study, from international, to national, to local level of engagement.”

Integrating a PhD with work and life

A PhD requires a lot of hard work and effort, to the point that the lines between studies, work, and life become blurred. Dr Venter acknowledged that she tried to balance work/life and study, but “I was not very good at it”. 
Passion, patience, peace, perseverance, positivity, and prayer are good principles to maintain when you are in the process of completing a PhD. – Dr Karen Venter 

She elaborates, “Studying became an integrated part of my work and life.  For the duration of my studies, I started working at 03:00 and I also did not watch any television.” She did, however, make time for herself by joining the wellness workout programme presented by the UFS, enjoyed gardening, and playing with her grandchildren. “I also tried to rest one day over weekends, and made time to praise and worship, which energised me for the next week,” she adds. 

“Passion, patience, peace, perseverance, positivity, and prayer are good principles to maintain when you are in the process of completing a PhD, she believes. 

Dr Venter says that although writing a PhD is indeed lonely, it is also an exciting journey, “especially when you reach those moments of breakthrough that can only come to life after deep reflection.” She also describes it as a deep spiritual journey. “Almost like walking in and out of a labyrinth – and where many hours become equal to a breath.

She is very grateful to her supervisors, Dr Somarie Holtzhausen, Prof Mabel Erasmus, and Dr Elanie Myburgh. “I deeply honour and salute you for your unconditional and continuous coaching, compassion, and care – guiding, supporting, motivating, mentoring, and keeping me grounded until I completed the journey.”

 

 


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept